FINWIRES · TerminalLIVE
FINWIRES

株価下落を受け、スティフェル・カナダはダララマの投資判断を「買い」に引き上げ、目標株価を190.00カナダドルに引き上げた。

By

-- スティフェル・カナダは火曜日、ダララマ(DOL.TO)株の投資判断を「中立」から「買い」に引き上げ、目標株価も180.00カナダドルから190.00カナダドルに引き上げた。これは同社株の下落を受けた措置である。 「ダララマの株価は52週安値付近にあり、投資家にとって魅力的なエントリーポイントとなっていると当社は考えています。以下の理由から、投資判断を『買い』に変更します。(1)株価収益率(PER)は2026年1月の高値39倍から低下し、現在は29.5倍で、過去2年間の平均33倍を下回っています。(2)イラン紛争に起因する今後1年間の大幅なインフレシナリオにおいて、ダララマは市場シェアを拡大する可能性が高いです。カナダ国民はドルをより有効活用するために、ダララマでの買い物を増やすと予想されます。(3)最近のインサイダーによる株式購入は心強い兆候です。CFOとCEOはそれぞれ174ドルと175ドルで株式を購入しており、これは現在の株価水準よりも高い水準です。したがって、より妥当な株価水準とインフレ圧力によるダララマの市場シェア拡大の可能性を考慮し、投資判断を『買い』に変更し、目標株価を10ドル引き上げて190ドルとします」と、アナリストのマーティン・ランドリー氏は述べています。 (は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください:https://www..com/contact-us

Price: $172.75, Change: $+2.26, Percent Change: +1.33%

Related Articles

Australia

American Electric Power CEO Says Speed to Market Key Issue in Load Connection

American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%

$AEP
Australia

MGE Energy Q1 Earnings, Revenue Rise

MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%

$MGEE
Research

Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.

$PFE